A recent phase I clinical in HNSCC patients (NCT02274155) demonstrated that anti-OX40 administration was well tolerated and increased the infiltration of activated CD4+ and CD8+T cells (61). This evidence concerns the gene CD4 and head and neck squamous cell carcinoma.